Rhode Island 2024 Regular Session

Rhode Island House Bill H8220

Introduced
5/1/24  

Caption

Creates the Rhode Island drug cost review commission.

Impact

If enacted, H8220 would significantly alter how prescription drug pricing is managed within the state, potentially lowering costs for consumers and healthcare systems. By establishing a formal review process, the bill empowers the DCR commission to set reimbursement rates that may help mitigate excessive pricing. This legislative approach mirrors systems in other regions, like Canada, where drug costs are more controlled. As such, it presents a proactive measure by the Rhode Island government to enhance healthcare affordability for its citizens.

Summary

House Bill H8220 establishes the Rhode Island Drug Cost Review Commission (DCR commission), aimed at addressing the rising costs of prescription drugs. The commission will be responsible for reviewing prices set by drug manufacturers and determining if they are affordable based on several criteria. This is in response to concerns regarding the monopolistic tendencies in the pharmaceutical market and the impact of high drug prices on residents, employers, and local governments. The bill also outlines the commission's powers, member appointments, and operational protocols, ensuring public accessibility to data while balancing proprietary interests of pharmaceutical companies.

Contention

Despite its intentions, the bill faces scrutiny and debate. Proponents argue it addresses an urgent public health issue, seeking to protect consumers from excessive drug costs and providing a structured review process. However, opponents could perceive it as an encroachment on free-market principles, fearing that rigorous state intervention may deter pharmaceutical investments or limit the availability of new drugs. As the bill moves forward, these points of contention will likely shape discussions around healthcare regulation and economic impacts within the state.

Companion Bills

No companion bills found.

Previously Filed As

RI H5104

Rhode Island Food, Drugs, And Cosmetics Act

RI H5495

The Rhode Island Health Care Reform Act Of 2004 -- Health Insurance Oversight

RI S0290

The Rhode Island Health Care Reform Act Of 2004 -- Health Insurance Oversight

RI H5079

Pharmaceutical Cost Transparency

RI H5678

The Rhode Island Health Care Reform Act Of 2004 -- Health Insurance Oversight

RI S0991

Rhode Island Public Transit Authority

RI S0566

The Rhode Island Health Care Reform Act Of 2004 -- Health Insurance Oversight

RI H5486

The Rhode Island Cannabis Act

RI H5839

Rhode Island Business Corporation Act

RI H5224

House Resolution Creating A Special Legislative Commission To Study And Provide Recommendations Pertaining To Services And Coordination Of State Programs Relating To Older Adult Rhode Islanders (creates A 16 Member Commission To Study And Provide Recommendations For Services And The Coordination Of State Programs For Older Adult Rhode Islanders, And Report Back By May 7, 2024, And Expire On August, 2024.)

Similar Bills

RI S2719

Creates the Rhode Island drug cost review commission.

MS SB2012

Mississippi Health Care Cost Transparency Act; enact.

CA SB41

Pharmacy benefits.

CA SB17

Health care: prescription drug costs.

CA SB838

Health care: prescription drugs.

CA AB2984

Prescription drug cost sharing.

CA AB933

Prescription drug cost sharing.

TX HB2536

Relating to transparency related to drug costs.